Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants

Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009–2015

(2019) Soo-Han Choi et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

(2018) Kristen E Pascal et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study

(2018) Sumathi Sivapalasingam et al.   LANCET INFECTIOUS DISEASES

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

(2018) Natalie I Mazur et al.   LANCET INFECTIOUS DISEASES

Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field

(2018) Prasad S. Kulkarni et al.   VIRAL IMMUNOLOGY

Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China

(2018) Xiangpeng Chen et al.   Scientific Reports

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

(2017) Ting Shi et al.   LANCET

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

(2017) Qing Zhu et al.   Science Translational Medicine

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B

(2017) Anne M. Hause et al.   PLoS One

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis

(2015) Danielle B.L. Oliveira et al.   JOURNAL OF CLINICAL VIROLOGY

Phase 1 Study Evaluating Safety, Tolerability, Pharmacokinetics and Immunogenicity of REGN2222 in Healthy Adults: A New Human Monoclonal RSV-F Antibody for RSV Prevention

(2015) Sumathi Sivapalasingam et al.   Open Forum Infectious Diseases

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

(2014)   PEDIATRICS

Gene Sequence Variability of the Three Surface Proteins of Human Respiratory Syncytial Virus (HRSV) in Texas

(2014) Lorena I. Tapia et al.   PLoS One

Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

(2012) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab

(2011) Qing Zhu et al.   JOURNAL OF INFECTIOUS DISEASES